Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024

Rhea-AI Summary

Aurinia Pharmaceuticals Inc. (AUPH) is set to release its 2023 fourth quarter and full year financial and operational results on February 15, 2024. The management team will host a conference call/webcast to review the results and provide a general business update. Interested participants can access the webcast through the company's corporate website.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release 2023 fourth quarter and full year financial and operational results on Thursday, February 15, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial 877-407-9170 / +1 201-493-6756 (Toll-free U.S. & Canada). The audio webcast can also be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with high unmet medical needs that are impacted by autoimmune, kidney, and rare diseases. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240205594736/en/

Investor/Media Contact:

ir@auriniapharma.com



Media Inquiries:

Andrea Christopher

Corporate Communications Director, Aurinia

achristopher@auriniapharma.com

Source: Aurinia Pharmaceuticals Inc.

When will Aurinia Pharmaceuticals release its 2023 fourth quarter and full year financial and operational results?

Aurinia Pharmaceuticals will release its 2023 fourth quarter and full year financial and operational results on February 15, 2024.

How can interested participants access the conference call/webcast?

Interested participants can access the conference call/webcast through the 'News/Events' section of the Aurinia corporate website at www.auriniapharma.com.

What are the dial-in details for the conference call?

Interested participants can dial 877-407-9170 / +1 201-493-6756 (Toll-free U.S. & Canada) to join the conference call.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available on Aurinia’s website.